Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 217

Sort by

Sort Order Select

Journal Articles

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Herve Ghesquieres, MD PhD, Olivier Casasnovas, MD, Emmanuelle Nicolas-Virelizier, MD, Damaj Gandhi Laurent, MD PhD, Vincent Delwail, MD, Mohamed Touati, MD, Katell Le Du, MD, Franck Morschhauser, MD PhD, Christophe Bonnet, MD, Agathe Waultier-Rascalou, MD, Frederique Orsini-Piocelle, MD, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, MD PhD, Alexandra Traverse-Glehen, MD PhD, Philippe Quittet, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 2832.

https://doi.org/10.1182/blood-2019-129016

Published: 2019

Journal Articles

Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 547.

https://doi.org/10.1182/blood-2019-121584

Published: 2019

Journal Articles

RNA Sequencing of Hodgkin Lymphoma Reed-Sternberg Cells Uncovers a Plasma Cell Signature and Escape from NK Cell Recognition

Ethel Cesarman, MD PhD, Mikhail Roshal, MD PhD, Jonathan Reichel, PhD, Wagner Florian, PhD, Bhavneet Binder, Sakellarios Zairis, Jouliana Sadek, PhD, Joshua Brody, MD, Raul Rabadan, PhD, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 549.

https://doi.org/10.1182/blood-2019-131163

Published: 2019

Journal Articles

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, MD, Herv Ghesquieres, Lauriane Clement filliatre, MD, Philippe Quittet, MD, Franck Morschhauser, MD, Vincent Ribrag, MD, Veronique Edeline, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 132.

https://doi.org/10.1182/blood-2019-123925

Published: 2019

Journal Articles

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Cyprien Shyirambere, MD, Rebecca Deboer, MD, Yvan Butera, MD, Caitlin Driscoll, resident, Jean Bosco Bigirimana, Francois Regis Uwizeye, Temidayo Fadelu, MD, Paul H Park, MD, Alan Paciorek, Leslie E. Lehmann, MD, Lawrence N. Shulman, MD

Blood (2019) 134 (Supplement_1): 4053.

https://doi.org/10.1182/blood-2019-130780

Published: 2019

Journal Articles

Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis

Blood (2019) 134 (Supplement_1): 4027.

https://doi.org/10.1182/blood-2019-123572

Published: 2019

Journal Articles

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Anna Vanazzi, MD, Fedro Peccatori, MD, Barbara Buonomo, MD, Di Loreto Eugenia, MD, Giovanna Scarfone, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5289.

https://doi.org/10.1182/blood-2019-127391

Published: 2019

Journal Articles

Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens

Angie Mae Rodday, PhD, Theresa E. Hahn, PhD, Anita J Kumar, MDMS, Peter K Lindenauer, MD MSc, Jonathan W. Friedberg, MD, Andrew Matthew Evens, DO,MMSc, Susan K Parsons, MD MRP

Blood (2019) 134 (Supplement_1): 1563.

https://doi.org/10.1182/blood-2019-124141

Published: 2019

Journal Articles

Lymphocyte Co-Expression of CD38/HLA-DR Is a Marker for Anti-Tumor Activity in Hodgkin Lymphoma in Vitro : Evidence for a PD1-Independent Mechanism

Meret Henry, MDMS, Steven Buck, MS, Batool Al-Qanber, MD, Manisha Gadgeel, MBBS, MS, Sureyya Savasan, MD

Blood (2018) 132 (Supplement 1): 4129.

https://doi.org/10.1182/blood-2018-99-119299

Published: 2018

Journal Articles

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Danielle Canioni, MD, Pauline Brice, MD, Serge Bologna, MD, Laurent Voillat, MD, Jean Gabarre, MD, Olivier Casasnovas, MD, Alain Devidas, MD, Bertrand Coiffier, MD PhD, Malek Aoudjhane, MD, Bruno Audhuy, MD, Marc Andre, MD, Catherine Fortpied, MD, Patrice Carde, MD PhD, Nicolas Mounier, MD, Josette Briere, MD

Blood (2018) 132 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2018-99-118039

Published: 2018

Journal Articles

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Reyad Dada, MD, Aisha Alharbi, MD, Ehab Mosaaf, MD

Blood (2018) 132 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2018-99-110262

Published: 2018

Journal Articles

Real World Evidence in Relapsed/Refractory Classical Hodgkin Lymphoma Patients Who Are Ineligible for Stem Cell Transplant in the United States (US)

Joseph Feliciano, Nate Way, PhD, Gerald Engley, PharmD, Nilanjan Ghosh, MD PhD

Blood (2018) 132 (Supplement 1): 2268.

https://doi.org/10.1182/blood-2018-99-113682

Published: 2018

Journal Articles

Baseline Characteristics of 412 Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP)

Huilai Zhang, MD PhD, Yuqin Song, MD PhD, Aichun Liu, MD, Haiyan Yang, PhD, Xinan Cen, MD, Jun Zhu, MD PhD, Yi Wen, PhD

Blood (2018) 132 (Supplement 1): 5362.

https://doi.org/10.1182/blood-2018-99-112755

Published: 2018

Journal Articles

Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma

Akihiro Tamura, MD PhD, Makiko Yoshida, MD PhD, Nobuyuki Yamamoto, MD PhD, Nanako Nino, MD, Naoko Nakatani, MD, Takayuki Ichikawa, MD, Sayaka Nakamura, MD, Atsuro Saito, MD, Aiko Kozaki, MD, Kenji Kishimoto, MD, Toshiaki Ishida, MD PhD, Daiichiro Hasegawa, MD PhD, Yoshiyuki Kosaka, MD PhD

Blood (2018) 132 (Supplement 1): 5316.

https://doi.org/10.1182/blood-2018-99-110732

Published: 2018

Journal Articles

The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Khalid Nasser Al Hashmi, Kamla Alwahaibi, Murtadha K. Al-Khabori, BSc, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 5369.

https://doi.org/10.1182/blood-2018-99-114957

Published: 2018

Journal Articles

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Katagiri Seiichiro, MD PhD, Kenko Azuma, PhD, Yuu Saitoh, MD, Seiichiro Yoshizawa, MD PhD, Daigo Akahane, MD PhD, Hiroaki Fujimoto, MD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko.H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2018) 132 (Supplement 1): 5525.

https://doi.org/10.1182/blood-2018-99-113317

Published: 2018

Journal Articles

Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis

Zin W. Myint, MD, Runa Shrestha, MBBS, Quan Chen, Bin Huang, Amit Goldberg, MD, Reshma Ramlal, MD, Gregory Monohan, MD, Roger A. Fleischman, MD PhD, Roger H. Herzig, MD, Gerhard Carl Hildebrandt, MD, Hayder Saeed, MD

Blood (2018) 132 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2018-99-110988

Published: 2018

Journal Articles

Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA

Lieselot Buedts, Luc Mathieu Fornecker, Julio Finalet-Ferreiro, PhD, Luc Dehaspe, PhD, Thomas Tousseyn, MD PhD, Olivier Gheysens, MD PhD, Julien Lazarovici, MD, Rene-Olivier Casasnovas, MD, Christiane Copie, MD PhD, Gregor Verhoef, MD PhD, Sanne Smits, Joris Vermeesch, PhD, Marc Andre, MD PhD, Peter Vandenberghe, MD PhD

Blood (2018) 132 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2018-99-113402

Published: 2018

Journal Articles

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

VIT K Prochazka, MD, Lenka Henzlova, MD, Marie Lukasova, MD, Veronika Hanackova, MD, Eva Kriegova, Dr, assoc prof, Zuzana Mikulkova, Dr, Gabriela Gabcova, Dr, Jiri Minarik, MD PhD, Alice Sýkorová, MD PhD, Eva Krcalova, MD, Jiri Dolezal, MD assoc prof, Pavel Koranda, MD assoc prof, Tomas Papajik, MD prof

Blood (2018) 132 (Supplement 1): 2933.

https://doi.org/10.1182/blood-2018-99-115150

Published: 2018

Journal Articles

Outcomes of Cord Blood Transplantation for Adult Patients with Hodgkin Lymphoma, a Eurocord and EBMT Lymphoma Working Party Study

Blood (2017) 130 (Supplement 1): 3318.

https://doi.org/10.1182/blood.V130.Suppl_1.3318.3318

Published: 2017

NARROW

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

RNA Sequencing of Hodgkin Lymphoma Reed-Sternberg Cells Uncovers a Plasma Cell Signature and Escape from NK Cell Recognition

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda

Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens

Lymphocyte Co-Expression of CD38/HLA-DR Is a Marker for Anti-Tumor Activity in Hodgkin Lymphoma in Vitro : Evidence for a PD1-Independent Mechanism

Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Patients: Single Institutional Experience

Real World Evidence in Relapsed/Refractory Classical Hodgkin Lymphoma Patients Who Are Ineligible for Stem Cell Transplant in the United States (US)

Baseline Characteristics of 412 Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP)

Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma

The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells

Socioeconomic Disparities Affect Survival of Classical Hodgkin Lymphoma in a Statewide Cancer Registry Analysis

Unraveling the Landscape of Copy Number Aberrations in Hodgkin Lymphoma: A Joint KU Leuven and Lysa Study on Circulating Cell Free DNA

Metabolic Tumor Volume and Soluble Cytokines Levels in Newly Diagnosed Hodgkin Lymphoma: What It Brings into the Staging Precision?

Outcomes of Cord Blood Transplantation for Adult Patients with Hodgkin Lymphoma, a Eurocord and EBMT Lymphoma Working Party Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only